Another cholesterol drug seeks OTC status
Now Pravachol is up to the plate. It too will be unlikely to be approved for OTC status. The pharmaceuticals are desperate to salvage profits in light of their expiring statin patents.
ADVERTISEMENT
More in Uncategorized
Past Week
-
Retirement isn’t the end of medicine, it’s a second act [PODCAST]
-
The conflict of interest that discloses as nothing
-
Why acne, chin hair, and irregular cycles are more than an ovary problem [PODCAST]
-
Burnout or job dissatisfaction: 4 causes usually in play
-
Nurse advocacy: The shackles came off before he died
-
Health data privacy with AI starts before you press send
-
Past 6 Months
-
Why CDC opioid guidelines get the overdose data wrong
-
Retirement isn’t the end of medicine, it’s a second act [PODCAST]
-
Sensory processing in autism and the brain’s volume control
-
What maternity care deserts cost a town
-
Why medicine needs a national physician license now
-
A cold cost $945. The cost of primary care is broken.
-
Recent Posts
-
Health data privacy with AI starts before you press send
-
Oluyemisi Famuyiwa, MD, on fertility and PCOS: a KevinMD subscriber spotlight
-
AI and clinical judgment: why patients still trust doctors
-
Moral injury in medicine is an odyssey without Ithaca
-
Why hearing loss and brain health belong together
-
AI and assisted dying raise questions of accountability
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
